Swiss pharmaceutical giant Novartis has recently been on the receiving end of two significant enforcement actions: the first for violations of the Foreign Corrupt Practices Act; the second for violations of the False Claims Act and Anti-Kickback Statute.
Tom Fox details the bribery schemes and the internal control failures, outlines just how much Novartis has lost as a result and offers key takeaways for compliance practitioners.
Download the whitepaper below.
